Roy R. Hantgan

Cardiovascular disease is the leading cause of death in our society, and the major culprit is a blood clot formed by the unwarranted activation of the clotting cascade. While cardiologists can often restore normal blood flow through by widening the blocked artery and inserting a stent to keep it open, this approach require powerful anti-platelet drugs that can themselves cause hemorrhagic or thrombotic problems.

Research in my laboratory focuses on understanding, at the molecular level, how a class of these drugs --- integrin antagonists --- recognize their target receptor and how that interaction actually alters its structure and function. Our biophysical approach to translational research is designed to hasten the development of a new generation of safer and more effective integrin-targeted therapies.

As Director of the Macromolecular Interactions Core Laboratory, I also strive to make an array of biotechnologies “user-friendly” to my colleagues here at the medical school, at Wake Forest University, and to the wider national and international research community.

Roy Hantgan - integrin antagonists

Modeling integrin antagonists binding to their target aIIbb3 receptor. From Hantgan et al., Journal of Thrombosis and Haemostasis, 5: 542-550 (2007).

Quick Reference

Biochemistry

Phone 336-716-4689
Fax 336-716-7671

E-mail
biochemrecruit
@wakehealth.edu

Find A Doctor Ways to Give
Last Updated: 06-30-2014
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.